An exploratory study regarding the use of the biomarker DAT for image diagnosis of clear cell renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Ioflupane 123I (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Diagnostic use
- Acronyms RCCSCAN
- 24 Oct 2018 Status changed from recruiting to completed.
- 11 Aug 2017 Status changed from not yet recruiting to recruiting.
- 06 Mar 2017 New trial record